Jordana G. Fein, MD, MS

Jordana Fein, MD, MS, is a retina specialist at The Retina Group of Washington.

Articles by Jordana G. Fein, MD, MS

(Image credit: Uday Devgan; Jordana Fein; Carl Regillo; Ophthalmology Times) The One Thing: Lens options, the retina pipeline, and patients in the chair

The One Thing: IOL choices, gene therapy and TKI trials, the patient in the chair | Episode 5

ByUday Devgan, MD, FACS,Jordana G. Fein, MD, MS,Carl D. Regillo, MD, FASRS,Sheryl Stevenson

November 4th 2026

Uday Devgan, MD, FACS, Jordana G. Fein, MD, MS, and Carl D. Regillo, MD, FASRS, point to IOL education, emerging retina therapies, and treatment burden.

Practical ways to extend anti-VEGF control in RVO, AMD, and DME

ByJordana G. Fein, MD, MS,Sheryl Stevenson

October 30th 2026

Jordana G. Fein, MD, MS, points to agent selection, payer requirements, and real-world treatment response across 3 retina cases.

Jordana Fein, MD, MS | ASRS 2026 | Ophthalmology Times Video

ASRS 2026: Aflibercept 8 mg holds vision gains with up to 3 fewer injections in macular edema following RVO

ByJordana G. Fein, MD, MS,Lucia Gambuzza

July 31st 2026

Jordana Fein, MD, MS, presented 64-week QUASAR data showing aflibercept 8 mg sustained visual acuity gains with up to 3 fewer injections than aflibercept 2 mg in macular edema following RVO.